# Ring Therapeutics

> Ring Therapeutics is a Cambridge, Massachusetts biotechnology company founded by Flagship Pioneering to build a new class of gene therapy delivery vectors from anelloviruses - the most abundant and diverse family of viruses that naturally and harmlessly live inside the human body. Because these commensal viruses evade the immune system, Ring's AnelloVector platform aims to solve gene therapy's biggest limitations: the inability to re-dose patients, pre-existing immunity, and narrow tissue targeting. Through its Anellogy discovery platform and AnelloBricks in-vitro manufacturing technology, Ring is engineering re-dosable, tissue-specific, scalable vectors intended to carry a wide range of therapeutic payloads.

- **Founded:** 2017
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** Avak Kahvejian (Founding CEO, Flagship Pioneering Partner), Erica Weinstein (Founding Head of Innovation), Noubar Afeyan (Co-founder & Chairman, Founder & CEO of Flagship Pioneering)
- **Team size:** ~45 employees
- **Products:** Anellogy Platform, AnelloVector, AnelloBricks, SATURN System
- **Notable:** Built the world's largest anellovirus database, sequencing 5,000+ anelloviruses from human samples., Raised over $253 million in total funding since founding., Published the first gene delivery vector system based on a human commensal virus (bioRxiv, April 2024).

## Products & services

- **Anellogy Platform** — Discovery and engineering platform that mines the human commensal virome to identify and design AnelloVector candidates with tissue-specific tropism and re-dosing potential.
- **AnelloVector** — Gene delivery vectors engineered from human anelloviruses, designed to evade pre-existing immunity, target specific tissues, and be re-administered.
- **AnelloBricks** — In-vitro assembly and manufacturing technology that produces AnelloVectors at scale with expanded payload versatility and dramatically lower cost.
- **SATURN System** — Self-Amplifying Trans-complementation of a Universal Recombinant aNellovector - a system that packages a vector payload into capsids from multiple anelloviruses.

## Achievements

- Built the world's largest anellovirus database, sequencing 5,000+ anelloviruses from human samples.
- Raised over $253 million in total funding since founding.
- Published the first gene delivery vector system based on a human commensal virus (bioRxiv, April 2024).
- Demonstrated durable vector expression for nine months after subretinal administration in mice.
- Achieved expression comparable to dose-matched AAV9 via intracerebroventricular delivery in preclinical studies.
- Presented new AnelloBricks manufacturing data at ASGCT 2025 showing scalable, lower-cost production and expanded payload versatility.

## Latest updates

- **2025-05** — Presented new data on the AnelloBricks in-vitro manufacturing platform at the 28th Annual ASGCT Conference, showing scalable production and expanded payload versatility beyond the natural single-stranded DNA anellovirus genome.
- **2025-01** — CFO Christopher McNulty assumed the role of Interim CEO as prior CEO Tuyen Ong moved to an advisory role amid a company restructuring.
- **2024-04** — Published a preprint in bioRxiv describing the SATURN system, the first gene delivery vector based on a human commensal anellovirus.

## Links

- Website: https://ringtx.com
- LinkedIn: http://www.linkedin.com/company/ring-therapeutics
- Twitter/X: https://twitter.com/ring_tx

---

Profile page: https://yespress.io/ring-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-07-18